{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:20:41Z","timestamp":1787750441541,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Loncastuximab tesirine (LT) is a CD19-directed antibody\u2013drug conjugate approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma. We report a case of a persistent, diffuse telangiectatic eruption that developed shortly after initiation of LT. Histopathologic examination revealed mild epidermal thinning with superficial ectatic vessels, large conspicuous fibroblasts, solar elastosis, and scattered dermal melanophages. This case highlights a distinctive, minimally inflammatory, vascular-predominant reaction pattern associated with LT. This morphology has been only recently recognized as a potential adverse effect of antibody\u2013drug conjugate medications, with very few published literature on the subject. Because the use of antibody\u2013drug conjugates continues to expand, recognition of this pattern is important, particularly given its persistence even after therapy cessation and limited response to corticosteroid treatment.<\/jats:p>","DOI":"10.1097\/dad.0000000000003317","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:00:20Z","timestamp":1782457220000},"page":"675-677","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Persistent Diffuse Telangiectatic Eruption Associated With Loncastuximab Tesirine"],"prefix":"10.1097","volume":"48","author":[{"given":"Sarah","family":"John","sequence":"first","affiliation":[{"name":"Penn State College of Medicine, Hershey, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Heinly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Penn State Health, Hershey, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Helm","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Penn State Health, Hershey, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Helm","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Penn State Health, Hershey, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"R1-20260819","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"R2-20260819","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00228-021-03253-3","article-title":"Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma","volume":"78","author":"Xu","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"R3-20260819","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cup.14327","article-title":"The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy","volume":"50","author":"Seervai","year":"2023","journal-title":"J Cutan Pathol"},{"key":"R4-20260819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2024.08.013","article-title":"Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma","volume":"53","author":"Seervai","year":"2024","journal-title":"JAAD Case Rep"},{"key":"R5-20260819","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jamadermatol.2020.0208","article-title":"Diffuse telangiectatic rash associated with novel antibody drug conjugate therapies","volume":"156","author":"Sorensen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R6-20260819","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/ijd.13836","article-title":"Phototoxic drug reaction with the novel agent rovalpituzumab tesirine","volume":"57","author":"Hou","year":"2018","journal-title":"Int J Dermatol"},{"key":"R7-20260819","first-page":"13","article-title":"Generalized essential telangiectasia","volume":"18","author":"Gordon Spratt","year":"2012","journal-title":"Dermatol Online J"},{"key":"R8-20260819","first-page":"49","article-title":"Cutaneous collagenous vasculopathy","volume":"8","author":"Brady","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"R9-20260819","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamadermatol.2024.2324","article-title":"Cutaneous collagenous vasculopathy associated with antibody-drug conjugate treatment","volume":"160","author":"Michelerio","year":"2024","journal-title":"JAMA Dermatol"},{"key":"R10-20260819","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0190-9622(89)70028-1","article-title":"Subacute radiation dermatitis: a histologic imitator of acute cutaneous graft-versus-host disease","volume":"20","author":"LeBoit","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"R11-20260819","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.seminoncol.2022.04.001","article-title":"Radiation recall dermatitis: a review of the literature","volume":"49","author":"Bhangoo","year":"2022","journal-title":"Semin Oncol"},{"key":"R12-20260819","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/120347540200600603","article-title":"Histopathologic features seen with radiation recall or enhancement eruptions","volume":"6","author":"Smith","year":"2002","journal-title":"J Cutan Med Surg"},{"key":"R13-20260819","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.clindermatol.2014.02.014","article-title":"Chronic actinic damage of facial skin","volume":"32","author":"Bila\u00e7","year":"2014","journal-title":"Clin Dermatol"},{"key":"R14-20260819","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R15-20260819","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaad.2024.07.1463","article-title":"Antibody-drug conjugates: a review of cutaneous adverse effects","volume":"91","author":"Saberi","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:33:52Z","timestamp":1787747632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DAD.0000000000003317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003317","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}